Related Experiment Videos
Costimulatory molecules as adjuvants for immunotherapy
James W Hodge1, John W Greiner, Kwong-Yok Tsang
1Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1750, USA. jh241d@nih.gov
Frontiers in Bioscience : a Journal and Virtual Library
|September 9, 2005
Summary
Enhancing cancer vaccines involves boosting T-cell responses against tumor-associated antigens (TAAs). Strategies include using viral vectors and T-cell costimulation to improve immunotherapy effectiveness.
Area of Science:
- Immunology
- Oncology
- Vaccinology
Background:
- Tumor-associated antigens (TAAs) are poorly immunogenic, limiting natural anti-tumor immune responses.
- Effective cancer vaccines require strategies to significantly enhance T-cell activation against TAAs.
Purpose of the Study:
- To review current strategies for enhancing TAA immunogenicity for cancer vaccines.
- To focus on the role of costimulatory molecules as adjuvants in cancer immunotherapy.
Main Methods:
- Utilizing poxvirus vectors to deliver TAA transgenes.
- Employing diversified prime-boost vaccination strategies with different vectors.
- Incorporating T-cell costimulation molecules via viral vectors.
- Modifying TAA amino acid sequences to improve immune recognition.
- Using cytokines, such as GM-CSF, as biologic adjuvants.
Main Results:
- Multiple approaches are being investigated to overcome TAA non-immunogenicity.
- Viral vectors and T-cell costimulation show promise in enhancing anti-tumor immunity.
- Cytokines like GM-CSF can act as effective biologic adjuvants.
Conclusions:
- Enhancing TAA immunogenicity is crucial for developing effective cancer vaccines.
- Costimulatory molecules represent a key strategy for cancer vaccine adjuvants and immunomodulation.